Q2 2026 saw revenue rise 17.2% year-over-year to $707.3 million, with net income up to $121.4 million and EBITDA margin steady at 21.7%. Full-year 2026 guidance projects up to 14% revenue growth and EPS between $17.25 and $17.95.Original document: Medpace Holdings, Inc. [MEDP] SEC 8-K Current Repor…
Q2 2026 saw revenue rise 17.2% year-over-year to $707.3 million, with net income up to $121.4 million and EBITDA margin steady at 21.7%. Full-year 2026 guidance projects up to 14% revenue growth and EPS between $17.25 and $17.95.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.